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Evidence from several clinical trials suggests that n-3 polyunsaturated fatty acid (n-3 PUFA) supple-
mentation during cancer chemotherapy improves patient outcomes related to chemotherapy tolerability,
regardless of the type of chemotherapy used. While the effects of n-3 PUFA supplementation during
chemotherapy have been the subject of several reviews, the mechanisms by which n-3 PUFA improve
patient responses through improved chemotherapy tolerability are unclear. There are several barriers
currently hindering interpretation and comparison of studies, including small sample sizes, poor patient
compliance, and variation in supplementation format and dose. Expansion of standard-of-care for spe-
ciﬁc patient populations to include n-3 PUFA supplementation concurrent with chemotherapy may
reduce costs associated with delayed treatment, toxicities and unplanned hospitalization during cancer
chemotherapy. The purpose of this review is to identify barriers to understanding mechanisms of host
protection, highlight considerations for future clinical trials, as well as to propose potential mechanisms
by which n-3 PUFA supplementation improves chemotherapy tolerability and ultimately patient
outcomes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
1.1. n-3 polyunsaturated fatty acids and human health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
1.2. Side effects of chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
2. Current evidence supporting n-3 PUFA supplementation during chemotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
2.1. Clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
2.1.1. Clinical outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
2.1.2. Inflammatory status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
2.1.3. Nutrition impact symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
2.1.4. Toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3. Potential mechanisms of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.1. Inflammation and immune responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.2. Maintenance of gut health and modification of the microbiome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.3. Attenuation of skeletal muscle mass depletion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
3.4. Modulation of neurological functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4. Current barriers to defining mechanisms of action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111icosapentaenoic acid; NSCLC,
l supplement; PUFA, poly-
R-g, peroxisome proliferator
nd), karen.martins@ualberta.
zurak).
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S.L. Morland et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 107e1161084.1. Sample size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.2. Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3. Type of supplement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.4. Supplement content . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5. Considerations for future clinical trial designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.1. Sample size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.2. Dietary analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.3. Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.4. Supplement content and incorporation of n-3 PUFA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
5.5. Outcome measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5.6. Dose response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6. Fish oil supplementation and chemotherapy-related healthcare costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.1. Fish oil supplementation as standard of care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
6.2. Examples of potential healthcare cost savings with fish oil supplementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
7. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1141. Introduction
1.1. n-3 polyunsaturated fatty acids and human health
The n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentae-
noic acid (EPA; 20:5n-3) and docosohexaenoic acid (DHA; 22:6n-3)
have been the focus of several clinical trials in a variety of healthy
and disease populations due to their numerous beneﬁts to human
health (reviewed by Ref. [1]). Plant n-3 PUFA, alpha-linolenic acid
(18:3n-3) is a dietary essential fatty acid that provides the substrate
for enzymatic conversion to EPA and DHA in humans. However,
conversion from alpha-linolenic acid may not provide adequate
levels of EPA and DHA in humans with disease [2]. The occasional
consumption of dietary sources of EPA and DHA, such as cold water
fatty ﬁsh, may not provide adequate amounts of these fatty acids.
Direct provision of EPA and DHA through supplementation may
therefore beneﬁt human health [3].
PUFA are a component of every cell membrane in the body;
dietary n-3 PUFA are incorporated into cell membrane phospho-
lipids in a dose-dependent manner, and modify host fatty acid
proﬁles by decreasing the proportion of n-6 PUFA such as arach-
idonic acid [3]. Alteration of membrane composition inﬂuences
membrane ﬂuidity, receptor activity, signalling molecule produc-
tion and lipid mediator production (reviewed by Ref. [3]) to evoke
alterations in metabolism at the cellular and tissue levels.1.2. Side effects of chemotherapy
There are several different effective modalities used to treat
neoplasms, including surgery, radiation therapy and chemotherapy.
While a positive relationship has been shown to exist between the
total platinum dose delivered in adjuvant chemotherapy and
overall survival [4], severe toxic side effects can lead to poorer
chemotherapy outcomes such as fewer courses of chemotherapy
delivered, dose reductions, treatment delays and decreases in
overall treatment time, thereby interrupting the most beneﬁcial
course of treatment [4e6]. Unfortunately, there are a number of
side effects related to chemotherapy. Apart from graded toxicities
included in the National Cancer Institute Common Toxicity Criteria
[7], additional side effects include decreased quality of life [8,9],
changes in immune and inﬂammatory markers [10,11], higher
nutritional impact symptoms and decline of nutritional status [9].
Collectively, it appears that improving chemotherapy tolerability
could lead to maintenance of the most effective levels of dosing,
increase adherence to chemotherapy schedules and improve thetherapeutic index of treatments, ultimately improving patient
outcomes.
The n-3 PUFA, EPA and DHA have been applied as an adjunct to
chemotherapy in cancer patients and have been shown to improve
the response of the tumor to drug treatment in a variety of settings
while protecting the host from toxicities associated with the drug
(recent reviews [12e23]). The collective evidence in humans sug-
gests n-3 PUFA supplementation enhances drug efﬁcacy to the
tumors as well as improving other important clinical outcomes
such as maintenance of muscle and quality of life. While these re-
views make different conclusions regarding how patient outcomes
were improved, almost all have highlighted the need for further
clinical trials to optimize supplement dosage and determine
mechanisms of action [13e22]. The purpose of this review is to
identify potential targets inﬂuenced by n-3 PUFA supplementation
during chemotherapy, with a focus on human evidence reporting a
reduction in side effects. We identify barriers to conducting clinical
trials, and highlight considerations for future trials that are
required to deﬁne optimal timing, dose and format of n-3 PUFA
supplementation during oncological treatment. As the focus of the
current review is on clinical studies, we have not included data on
preclinical models; we direct readers interested in this topic to
reviews on the experimental literature [24e27].
2. Current evidence supporting n-3 PUFA supplementation
during chemotherapy
2.1. Clinical trials
Several recent clinical trials have shown improved chemo-
therapy tolerability and patient outcomes associated with adjuvant
n-3 PUFA supplementation. Although these trials were performed
in different cancer populations using a variety of chemotherapy
regimens, improvements were observed in all interventions
[28e41] (Table 1). Highlights of these improvements are brieﬂy
discussed below.
2.1.1. Clinical outcomes
Cancer is an important health issue that inﬂuences quality of life
and survival. Strikingly, breast cancer patients with high incorpo-
ration of supplemented DHA (i.e. extent of DHA increase above the
median of 2.5% of total fatty acids) experienced longer time to
disease progression (8.7 months vs 3.5 months) and signiﬁcantly
longer survival (34 months vs 18 months) compared to patients
with lower incorporation of supplemented DHA [31]. Additionally,
Table 1
Clinical trials investigating the effects of adjuvant n-3 PUFA supplementation on patient outcomes during chemotherapy.
Author (year) Study design Patient
population
Chemotherapy Intervention (dose/duration) Findings (n-3 PUFA/
H-DHA group)
Advised Actual (% of
advised dose)
Arshad et al.
(2015) [28]
Open label, single
arm, phase II trial
Advanced
pancreatic
cancer (n ¼ 50)
Gemcitabine n-3 PUFA-rich lipid emulsion
infusion (4.3e8.6 g of EPA þ DHA)/
day/16 weeks)
20%e40% of the
advised dose
was received.
10% [ QOL
(EORTC-QLQC30/
EORTC-QLQ-PAN26).
Bauer et al.
(2005) [29]
Open label, single
arm, pilot trial
Pancreatic
cancer (n ¼ 5),
lung cancer
(n ¼ 2)
Gemcitabine with or without another
chemotherapy agent
n-3 PUFA enriched ONS (1.1 g EPA;
DHA not reported/day/8 weeks)
31%e300% of
the advised
dose was
consumed.
[ QOL (EORTC-
QLQC30).
[ nutritional status
(PG-SGA).
[ performance
status (KPS).
Bonatto et al.
(2012) [30]
Randomized,
open label, two
arm trial
GI cancer
(n ¼ 28), other
cancers
(n ¼ 10)
5-Fluorouracil, Leucovorin Gelatin capsules (0.3 g EPA þ 0.4 g
DHA/day/8 weeks)
Not reported. Maintenance of
neutrophil number
and function.
Weight
maintenance.
Bougnoux
et al. (2009)
[31]
Open label, single
arm, phase II trial
Metastatic
breast cancer
(n ¼ 25)
Cyclophospho-amide, 5-Fluorouracil,
Epirubicin
Gelatin capsules (1.8 g DHA/day/5
months)
90% compliance
to the advised
dose.
[ time to
progression.
[ overall survival.
Y anemia and
thrombocytopenia.
Finocchiaro
et al. (2012)
[32]
Randomized,
placebo
controlled,
double blind trial
Advanced
NSCLC (n ¼ 27)
Cisplatin and Gemcitabine Gelatin capsules (2.0 g EPA þ 1.4 g
DHA/day/66 days)
Not reported. [ weight.
Y plasma CRP and IL-
6.
Ghoreishi
et al. (2012)
[33]
Randomized,
placebo
controlled,
double blind trial
Positive node
breast cancer
(n ¼ 57)
Paclitaxel Gelatin capsules (0.2 g EPA þ 1.0 g
DHA/day/16 weeks)
65% of the
advised dose
was
administered.
Y peripheral
neuropathy.
Mocellin et al.
(2013) [34]
Randomized,
controlled
clinical trial
Colorectal
cancer (n ¼ 11)
Xeloda. Oxaliplatin, 5-Fluorouracil and/or
Leucovorin.
Gelatin ﬁsh oil capsules (0.4 g
EPA þ 0.2 g DHA/day/9 weeks)
Not reported. Y serum CRP.
Y CRP/albumin ratio.
Weight
maintenance.
Murphy et al.
(2011)
[35,36]
Open label, two
arm trial
Stage IIIB or IV
NSCLC (n ¼ 46)
Platinum-based doublet therapy. Gelatin capsules (2.2 g EPA and
0.2 g DHA) or liquid ﬁsh oil (2.2 g
EPA and 0.5 g DHA/day/10 weeks)
>95%
compliance to
the advised
dose.
[ chemotherapy
cycles received.
[ clinical beneﬁt.
[ chemotherapy
response rate.
Maintenance of total
body weight and
skeletal muscle
mass.
Read et al.
(2007) [37]
Open label, single
arm, phase II trial
Stage IV
colorectal
cancer (n ¼ 23)
Not speciﬁed n-3 PUFA-enriched ONS (2.2 g
EPA þ 0.9 g DHA/day/9 weeks)
85% of the
advised dose
was consumed.
Weight
maintenance.
Y CRP.
[ QOL energy
(DATA).
Sanchez-Lara
et al. (2014)
[38]
Randomized,
controlled, open-
label trial.
Stage IIIb or IV
NSCLC (n ¼ 84)
Paclitaxel þ Cisplatin/Carboplatin n-3 PUFA-enriched ONS (2.2 g EPAa
þ 1.0 g DHAa/day/8 weeks)
70% of the
advised dose
was consumed.
Y serum CRP and
TNF-alpha.
Y NLR and PLR.
Y fatigue and loss of
appetite.
[ energy and protein
intake.
Weight
maintenance.
Y neuropathy.
Trabal et al.
(2010) [39]
Randomized,
controlled, open-
label trial
Stage IV
colorectal
cancer (n ¼ 11)
5-Fluorouracil þ Oxaliplatin þ Folinic acid
OR Capecitabine
n-3 PUFA-enriched ONS (2.0 g
EPA þ 0.9 g DHAa/day/12 weeks)
80% of the
advised dose
was consumed.
[ weight.
van der Meij
et al. (2010)
[40], (2012)
[41]
Randomized,
double-blind,
placebo-
controlled trial
Stage IIIa-N2 or
IIIb NSCLC
(n ¼ 42)
Cisplatin-based doublet OR Docetaxel,
Cisplatin OR Induction-based
chemotherapy, Bevacizumab; Concurrent
radiotherapy
n-3 PUFA-enriched ONS (2.0 g
EPA þ 0.9 g DHA/day/5 weeks)
50% of the
advised dose
was consumed.
[ QOL (EORTC-
QLQC30).
Y nausea and
vomiting.
[energy intake.
Weight
maintenance.
Y FFM depletion.
a Doses of EPA and/or DHAwere not reported by the authors. The amounts of EPA and/or DHA calculated for Sanchez-Lara et al. [38] and Trabal et al. [39] were based on the
composition of the n-3 PUFA-enriched products as shown in Barber et al. [50] and van der Meij et al. [40], respectively. CRP, C-reactive protein; DATA, disease and treatment
assessment form; DHA, docosohexaenoic acid; EORTC-QLQ, European Organisation for Research and Treatment of Cancer e Quality of Life Questionnaire; EPA, eicosa-
pentaenoic acid; FFM, fat-free mass; GI, gastrointestinal; H-DHA, high-DHA incorporation group; IL-6, interleukin 6; KPS, Karnofsky performance status; NLR, neutrophil/
lymphocyte ratio; NSCLC, non-small cell lung cancer; ONS, oral nutritional supplement; PG-SGA, patient-generated subjective global assessment; PLR, platelet/lymphocyte
ratio; PUFA, polyunsaturated fatty acid; QOL, quality of life.
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S.L. Morland et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 107e116110lung cancer patients receiving platinum-based doublet chemo-
therapy with concurrent n-3 PUFA supplementation received more
chemotherapy cycles, experienced increased clinical beneﬁt (80% vs
42%) and had a signiﬁcantly greater tumor response rate compared
with the control group (60% vs 26%) [35]. In a clinical pilot trial [29],
pancreatic and lung cancer patients receiving an n-3 PUFA enriched
oral nutritional supplement (ONS) had a signiﬁcantly improved
performance status, which has been shown to correlate with
response and tolerability to chemotherapy, and outcomes in cancer
patients [42]. Quality of life evaluates general well-being, and a 10%
improvement in quality of life indices is recognized as being clini-
cally signiﬁcant. Arshad et al. [28] found that over 50% of advanced
pancreatic cancer patients whowere provided with n-3 PUFA had a
10% or greater improvement in quality of life sustained for at least 4
weeks. Similarly, providing n-3 PUFA to cachectic pancreatic and
non-small-cell lung cancer patients [29,41], and advanced colo-
rectal cancer patients [37] resulted in signiﬁcantly better quality of
life and global health status.
2.1.2. Inﬂammatory status
Markers of immune and inﬂammatory status are often altered
during the course of chemotherapy [11]. C-reactive protein (CRP) is
a commonly used marker of inﬂammation that has been used to
prognosticate several cancers [43e46]; high levels of CRP indicate a
worse prognosis. The CRP/albumin ratio has also been shown to be
an independent predictor of overall survival in patients with cancer
[47,48]. N-3 PUFA supplementation in patients with colorectal
cancer showed signiﬁcantly lower CRP [34,37] and CRP/albumin
ratios [34]. Lung cancer patients supplementing with n-3 PUFA also
had signiﬁcantly reduced serum CRP levels after two [38] or three
[32] cycles of chemotherapy. In addition to reduced CRP levels, n-3
PUFA supplementation during chemotherapy reduced interleukin-
6, tumor necrosis factor-a, neutrophil/lymphocyte ratio, platelet/
lymphocyte ratio, and maintained neutrophil number and function
[30,32,38], collectively suggesting reduced pro-inﬂammatory sta-
tus in response to n-3 PUFA supplementation.
2.1.3. Nutrition impact symptoms
Chemotherapy is commonly associated with nutritional impact
symptoms, which encompass the broad spectrum of impediments
to oral nutritional intake, and may lead to inadequate consumption
of energy, protein and other important nutrients [9,49] which in
turn is associated with worse outcomes and lower quality of life [9].
Therefore, interventions that improve chemotherapy-induced
nutritional impact symptoms and nutritional status may improve
patient outcomes. A number of recent clinical trials have shown
that n-3 PUFA supplementation decreased the nutritional impact
symptoms of fatigue, appetite loss, and nausea and vomiting
[38,41], and improved measurements of nutritional status [29]
including increased overall energy and protein intake [29,38,40],
weight maintenance or gain [30,32,34,36e40], and attenuation of
fat-free mass depletion [36,40]. Collectively, these improvements
may play a key role in chemotherapy tolerability and overall patient
outcomes.
2.1.4. Toxicity
The National Cancer Institute Common Toxicity Criteria is a
standardized method for deﬁning adverse events and describing
the severity of toxicity for patients receiving cancer therapy [7].
Prescribed schedules of chemotherapy are often interrupted or
terminated due to chemotherapy-induced toxicities [4e6] and
therefore, supplements that reduce these toxicities may lead to
improved patient outcomes by enabling chemotherapy to be
delivered on course. N-3 PUFA supplementation was reported to
signiﬁcantly reduce the chemotherapy-related toxicities of anemiaand thrombocytopenia in breast cancer patients [31], and neurop-
athy in patients undergoing treatment for breast [33] and lung
cancer [38].
Presumed doses of EPA and DHA were not reported by the au-
thors [28,38,39]. The amounts of EPA and/or DHA calculated for
Sanchez-Lara et al. [38] and Trabal et al. [39] were based on the
composition of the n-3 PUFA-enriched products as shown in Barber
et al. [50] and van der Meij et al. [40], respectively. CRP, C-reactive
protein; DATA, disease and treatment assessment form; DHA,
docosohexaenoic acid; EORTC-QLQ, European Organisation for
Research and Treatment of Cancer e Quality of Life Questionnaire;
EPA, eicosapentaenoic acid; FFM, fat-free mass; GI, gastrointestinal;
H-DHA, high-DHA incorporation group; IL-6, interleukin 6; KPS,
Karnofsky performance status; NLR, neutrophil/lymphocyte ratio;
NSCLC, non-small cell lung cancer; ONS, oral nutritional supple-
ment; PG-SGA, patient-generated subjective global assessment;
PLR, platelet/lymphocyte ratio; PUFA, polyunsaturated fatty acid;
QOL, quality of life.
3. Potential mechanisms of action
3.1. Inﬂammation and immune responses
N-3 PUFA modulate the pattern of eicosanoid production and
both the intensity and duration of inﬂammatory responses [3]. N-6
PUFA-derived eicosanoids are well-characterized as pro-
inﬂammatory molecules, while n-3 PUFA such as EPA are typi-
cally associated with the production of less inﬂammatory lipid
mediators [51]. Thus, increasing the amount of dietary EPA and
DHA decreases the amount of substrate for n-6 PUFA-derived ei-
cosanoids, while increasing the substrate for n-3 PUFA-derived
eicosanoids and reducing the inﬂammatory proﬁle of the host
[51]. N-3 PUFA are also known ligands for peroxisome proliferator
activated receptor gamma (PPARg) [52]. This nuclear receptor plays
a role in a variety of physiological processes including immune
function [53]. N-3 PUFA decrease production of pro-inﬂammatory
cytokines such as tumor necrosis factor-a, interleukin-1b and
interleukin-6 [53]. A pro-inﬂammatory proﬁle is associated with
cancer development, and chemotherapy may exacerbate inﬂam-
mation [10,11]. Therefore, modulation of inﬂammatory proﬁles by
n-3 PUFA could potentially improve chemotherapy tolerability.
3.2. Maintenance of gut health and modiﬁcation of the microbiome
Use of chemotherapeutic agents such as irinotecan produces
dose-limiting toxicities associated with gastrointestinal distress
including nausea and vomiting, leading to loss of appetite and
diminished caloric intake [54]. The maintenance of nutritional
status through reduction of gastrointestinal side effects such as
nausea and vomiting may play a role in chemotherapy tolerability
and improved patient outcomes (reviewed by Ref. [55]). Dietary n-3
PUFA may be incorporated into enterocyte cell membranes and
subsequently modify gut barrier function and mucous production,
which has been demonstrated in animal models [56], but has yet to
be conﬁrmed as a mechanism of action in humans. Collection of
tissue samples before and after supplementation would enable
biological changes to be related to symptoms such as dietary intake,
nausea, vomiting and adherence to chemotherapy regime. How-
ever, access to human samples is limited, pointing to the need for
additional pre-clinical studies to further investigate this
mechanism.
Evidence is building to suggest that the gut microbiome is
altered in cancer patients [57] and plays a role in metabolism of
drugs and pharmacological agents (reviewed by Refs. [58,59]). As
such, n-3 PUFA supplementation has been shown to alter
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humans [62]. While this effect has not been evaluated in cancer
patients undergoing chemotherapy, it is possible that n-3 PUFA
exert a protective effect by favorably modifying the host micro-
biome and altering metabolism of chemotherapeutic agents. Al-
terations in drug metabolism may modify chemotherapy
tolerability in patients experiencing side-effects related to impaired
drug metabolism but this remains to be explored in humans.3.3. Attenuation of skeletal muscle mass depletion
Previous studies have demonstrated that a low amount of lean
body mass is associated with worse patient outcomes during
chemotherapy [6]. Chemotherapeutic agents that are metabolized
in water-soluble compartments are taken up into skeletal muscle
tissue. In patients with lower skeletal muscle mass, higher con-
centrations of water-soluble drugs are observed in skeletal muscle
tissue and are associatedwith increased dose-limiting toxicities [6].
Numerous studies report that treatment with n-3 PUFA helps to
maintain skeletal muscle mass in people with cancer [36,40,63,64].
There are several proposed mechanisms by which n-3 PUFA sup-
plementation inﬂuences maintenance of muscle mass, including
inhibition of catabolic stimuli through down-regulation of catabolic
cytokines and acute-phase proteins, improvement of insulin
sensitivity, improved metabolic ﬂexibility and modulation of
muscle-adipose mediators (reviewed by Refs. [65,66]). Therefore,
improved outcomes related to enhanced chemotherapy tolerability
could be mediated through an inﬂammation-independent main-
tenance of skeletal muscle mass associated with n-3 PUFA
supplementation.3.4. Modulation of neurological functions
DHA is a major component of neuronal phospholipids that
regulates signal transduction, neurotransmission and membrane
ﬂuidity [67]. Ghoreishi et al. [33] reported lower incidence of
paclitaxel-induced peripheral neuropathy with EPA/DHA supple-
mentation (0.2 g EPA/1.0 g DHA advised daily dose) inwomen being
treated for breast cancer. Similar effects have also been observed in
advanced lung cancer populations receiving an n-3 PUFA-enriched
ONS (2.2 g EPA/1.0 g DHA advised daily dose) during paclitaxel plus
cisplatin/carboplatin doublet chemotherapy [38]. Providing DHA
may enable neuronal recovery following chemotherapy-related
toxicities, thus allowing for decreased dose-reduction in response
to toxicity and improved adherence to chemotherapy schedule.
More research on the optimal dose and the requirement of DHA
and/or EPA for neurotoxicities is required.4. Current barriers to deﬁning mechanisms of action
4.1. Sample size
One of the principal barriers to performing clinical studies that
show clear mechanisms of action of n-3 PUFA in relation to
chemotherapy tolerability are difﬁculties associated with recruiting
and maintaining sufﬁcient study participants to ensure statistical
power of the study. Losses to follow-up may lead to substantial
declines in patient population, particularly in cancers with high
mortality rates or later stage diagnosis [35,68]. Many recent clinical
trials have focused on stage III and IV cancers undergoing concur-
rent chemotherapy/radiotherapy treatment [28,32,35,36,38e41]
which may be less likely to complete the intended study duration.4.2. Compliance
Lack of compliance to a prescribed daily n-3 PUFA dose is a
commonly reported limitation of clinical trials. Fearon et al. [68]
and Nogueira et al. [69] reported non-compliance in the form of
contamination between treatment and placebo groups. This may
have occurred from disclosure of the nutrient of interest to study
participants. Importantly, while patient self-reported consumption
records showed no difference in compliance between groups [68],
evidence of contamination in the form of over-the-counter “self-
supplementation” in the control group was revealed by elevated
plasma phospholipid n-3 PUFA levels [68,69]. Compliance has also
been shown to vary between different study designs. Fearon and
colleagues investigated the same type and advised dose of an n-3
PUFA-enriched ONS in patients with pancreatic cancer, ﬁrst in a
pilot open-label study [50] and then in a randomized controlled
trial [68]. They found that subjects consumed 95% of the advised
dose in the open-label study, but only 70% of the same advised dose
in the randomized controlled trial [50,68].
Participants also have lower compliance on higher doses of oil-
containing supplements (i.e. n-3 PUFA ﬁsh oil and placebo olive oil).
It appears that compliance is very poor with 9 g of encapsulated
oil per day [70e72], up to a maximum tolerated dose of 0.3 g of
encapsulated oil/kg of body weight/day, with gastrointestinal dose-
limiting toxicities [71]; this equates to a 70 kg cancer patient
tolerating up to 21 g of encapsulated oil per day. Conversely,6 g of
encapsulated oil per day has been reported to be well tolerated,
with compliance rates greater than 90% and no serious adverse
events being related to the study interventions [31,35,36,72]. Lower
compliance also appears to commonly occur with n-3 PUFA-
enriched ONS. On average, cancer patients only consumed 71% of
the recommended n-3 PUFA-enriched ONS per day [37e41,68].
Collectively, it appears that there are a number of barriers to
compliance that involve study design, dosing and type of supple-
ment. The types of compliance measurements can also potentially
have a signiﬁcant impact.
4.3. Type of supplement
Comparison of recent clinical trials in cancer patients under-
going chemotherapy is challenging due to the use of different
supplement formats and dosing, as well as limited reporting of the
EPA and DHA content. A variety of different supplementation
methods have been used, including liquid ﬁsh oil [35], soft gelatin
capsules [30e34,36], lipid infusions [28] and ONS with added n-3
PUFA [29,37,38,40,41]. Within these different supplement modal-
ities, various doses of total n-3 PUFA have been used, limited
reporting of EPA and DHA content has occurred, as well as different
ratios of EPA to DHA. As previously discussed, patient compliance is
also an issue, which often leads to consumption of n-3 PUFA that
differs from the prescribed dose [29,37e41,68]. N-3 PUFA-enriched
ONS have been used in several recent clinical trials [29,37e41,68].
These supplements provide calories, protein and total fat but have
been shown to displace regular foods from the patient's diet to
confound observed patient outcomes [68]. In other studies, n-3
PUFA-enriched ONS have been associated with increased caloric
intake [38,40,41]. Thus, it is difﬁcult to compare the results of ONS
interventions to other studies that examine addition of n-3 PUFA
without provision of calories, as it is unclear whether the improved
outcomes seen in the intervention groupwere attributable to the n-
3 PUFA or the increased caloric intake of those patients.
Although most clinical trials have provided n-3 PUFA supple-
ments orally, supplementation has also been provided intrave-
nously [28]. In a recent study, several participants experienced
nausea leading to provision of smaller doses of intravenous n-3
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effects are more likely to occur if lipid emulsions are administered
faster than the clearance capacity of the patient [73]. Therefore,
providing the same dose at a lower infusion rate may have
improved supplement tolerance and enabled better dose mainte-
nance. Intravenous provision of n-3 PUFA allows for rapid incor-
poration of fatty acids [74] that may be a way to maximize lipid
incorporation to achieve themost beneﬁcial effects. However, more
trials using this approach are required. It is also important to
consider that intravenous supplementation of n-3 PUFA bypasses
the gastrointestinal tract and could exert different effects than
orally provided supplements. Experimental evidence suggests that
dietary fatty acids could exert protective effects against certain
cancers through incorporation into the colonic epithelium and
subsequent alteration of miRNA expression proﬁles [75]. Therefore,
supplementation routes that bypass the gastrointestinal tract
should be interpreted with this in mind.
4.4. Supplement content
Emerging work would suggest that EPA and DHA may have
unique, but complementary effects. In prior work, the amounts of
both or one of the n-3 PUFA contained in a supplement have not
been reported (for example [38,39]), or simply reported as total n-3
PUFA [28,76]. This makes interpretation of data and comparisons to
other work challenging. For example, when the content of EPA, but
not DHA is listed in a supplement containing both n-3 PUFA [39],
any potential mechanisms of action attributed to EPAmay also have
been due to the unknown complementary or unique effects of DHA.
5. Considerations for future clinical trial designs
5.1. Sample size
A potential way to circumvent patient dropout and increase
sample size may be to open studies to patients with earlier disease
stages. Opening trials to a larger cohort of patients would increase
sample size, as well as enable comparison of chemotherapy toler-
ance and patient outcomes depending on how early in the disease
trajectory supplementation is initiated.
5.2. Dietary analysis
No clinical trials, to date, have evaluated habitual dietary intake
of n-3 PUFA prior to supplementation. N-3 and n-6 PUFA compete
for the same enzymes in biological pathways and the balance be-
tween n-3 and n-6 PUFA inﬂuences many metabolic pathways [3].
Introduction of dietary n-3 PUFA in a diet low in these fatty acids
would be expected to displace n-6 PUFA from pathways of eicos-
anoid synthesis, for example, by competing for enzyme active sites,
enabling synthesis of more n-3-derived eicosanoids [3]. This may in
turn result in the development of a more anti-inﬂammatory proﬁle.
Alternatively, a diet high in n-6 fatty acids may impede the effec-
tiveness of n-3 fatty acids. N-3 PUFA supplementation may also
modulate inﬂammatory responses by altering inﬂammatory cyto-
kine production through changes in PPARg expression [53]. While
recent studies have observed that n-3 PUFA supplementation is
associated with reduced levels of CRP leading to improved nutri-
tional status and chemotherapy tolerability [34,37,38], it is unclear
whether baseline dietary intake of n-3 PUFA played a role in this
association. Therefore, evaluation of baseline n-3 PUFA status may
be a relevant factor to consider when evaluatingmechanisms of n-3
PUFA supplementation related to chemotherapy tolerability. There
is now a wealth of studies that have reported EPA and DHA plasma
levels in free living healthy individuals (e.g. Refs. [77,78]) as well asin patients with cancer (e.g. Refs. [35,36,41,50]) that could be
applied as a frame of reference depending on the tumor types and
geographical region of the study.
5.3. Compliance
It appears that compliance to n-3 PUFA supplementationmay be
improved through study design, optimal dosing, and type of sup-
plement. For example, compliance has been shown to be improved
through open-label trials [35,36,50]. Patients given a cancer diag-
nosis may not be as willing to take the chance of being “random-
ized” to a supplement that will provide no beneﬁt, such as a placebo
(e.g. open-label [50] vs randomized [68]). Therefore, exploring the
possibility of more open-label trials that include an objective
measure of compliance, could be one way to this issue. To avoid
contamination in the form of over-the-counter “self-supplemen-
tation”, future randomized controlled trials could consider keeping
the nutrient being studied (i.e. n-3 PUFA) blinded to the
participants.
The dose that is optimal for an individual is not known; it may
depend on amount of muscle, baseline diet as well as genetics of
the particular individual. With those caveats in mind, based on n-3
PUFA tolerability, adverse event proﬁle and responses observed in
previous clinical trials [30,33e36,70e72], a daily dose containing
6 g of oil that provides at least 2 g EPA in the form of a gelatin
capsule supplement is proposed for cancer patients undergoing
chemotherapy as a starting point. Although the optimal dose of
DHA is currently not known, providing 1.8 g/day of DHA exclusively,
a dietary intake dose approximating the saturation level of plasma
phospholipid DHA concentrations [79], has been shown to be of
marked beneﬁt for breast cancer patients undergoing chemo-
therapy [31]. Previous studies have shown that use of gelatin
capsule supplements containing 6 g of oil facilitates markedly
greater compliance [31,34e36,72] compared with the use of9 g of
oil per day [70e72]. Gelatin capsules are inexpensive [80] and may
place less of a burden on the patient than intravenous n-3 PUFA
infusions or n-3 PUFA-enriched ONS. In addition, use of gelatin
capsules reduces the likelihood that improved patient outcomes
are the result of additional variables, such as provision of additional
protein and energy in ONS. Finally, gelatin capsules allow for the
inclusion of a comparable gelatin capsule placebo. It is important to
emphasize that future studies include baseline and post-
supplementation biomarkers of n-3 PUFA dietary intake, such as
plasma phospholipid or red blood cell EPA and DHA contents,
which increase in a dose-dependent manner in response to dietary
intake of their respective n-3 PUFA [79]. This information can be
used for direct measures of overall compliance to the supplemental
regime [32e36,40], and as a potential indicator of contamination by
over-the-counter n-3 PUFA use in control groups [68,69].
5.4. Supplement content and incorporation of n-3 PUFA
We encourage the reporting of both EPA and DHA contents in
supplements, as well as biomarker measurements of EPA and DHA
incorporation, regardless of the speciﬁc n-3 PUFA being evaluated.
In addition to its relevance as a biomarker of n-3 PUFA dietary
intake, plasma phospholipid EPA and DHA levels may also reﬂect
the peripheral availability of these n-3 PUFA for incorporation into
tissues, as dietary n-3 PUFA are incorporated into plasma phos-
pholipids after absorption for delivery to tissues. Senkal et al. [76]
reported signiﬁcant increases in the EPA and DHA content of
plasma phospholipids as well as all tissues analysed (i.e. liver, gut
mucosa, and tumor) in cancer patients who preoperatively
consumed an n-3 PUFA-enriched ONS (2.5 g n-3 PUFA/day/5 days)
compared with a control group. Of note, Bougnoux et al. [31]
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tion in metastatic breast cancer patients receiving an identical DHA
supplement dose, which resulted in signiﬁcant differences in pa-
tient outcomes; patients with high DHA incorporation had signif-
icantly greater time to progression and overall survival compared
with patients who had lowDHA incorporation. Although Bougnoux
et al. [31] did not include EPA in the supplement or report its
plasma phospholipid content, it should be mentioned that DHA
supplementation not only results in an increase in plasma phos-
pholipid DHA concentrations, but also appears to result in a linear
increase in plasma phospholipid EPA concentrations, most likely
occurring through metabolic retroconversion [79]. Collectively, the
reporting of both EPA and DHA contents in supplements, plasma
phospholipids and tissues, regardless of the speciﬁc n-3 PUFA of
interest may contribute important insight into potential mecha-
nisms of action contributing to patient outcomes.
5.5. Outcome measures
Currently, several different outcome measures are used in clin-
ical trials, many of which do not enable mechanisms of action to be
determined. Additional measures may include measurements of n-
3 PUFA incorporation into skeletal muscle or other tissues, changes
in gut physiology and microbiome, secondary messenger produc-
tion, changes in regulation of inﬂammatory genes and effects on
protein function related to host protection. Using discrete outcome
measures may enable determination of pathways and cellular
processes that are inﬂuenced by n-3 PUFA supplementation and
how these changes relate to chemotherapy tolerability and
improved patient outcomes.
5.6. Dose response
Although improved patient outcomes have been reported at
several n-3 PUFA doses [28e41] in a variety of chemotherapy reg-
imens, dose-response studies have not been performed in a sys-
tematic manner in the oncology setting.While several studies show
that patient outcomes are improved by provision of approximately
2 g EPA per day during chemotherapy [32,36,37,40,41], differences
in patient metabolism and physiology could lead to different re-
sponses at this dose. As mentioned, Bougnoux et al. [31] observed
wide variations in plasma phospholipid DHA incorporation in pa-
tients receiving identical supplement doses, resulting in signiﬁcant
differences in patient outcomes. Furthermore, the optimal dose of
DHA and optimal ratio of EPA:DHA are not known. Dose-response
studies are required to determine the effectiveness of n-3 PUFA
relative to factors such as baseline skeletal muscle mass, dietary
intake, inﬂammatory status and other underlying health issues
such as cardiovascular disease, diabetes and obesity. Determining
factors that inﬂuence patient responses at different supplement
doses would improve ability to apply an effective dose to improve
chemotherapy tolerability.
6. Fish oil supplementation and chemotherapy-related
healthcare costs
6.1. Fish oil supplementation as standard of care
Clinical trials have faced several barriers to demonstrating
mechanisms by which n-3 PUFA supplementation improves
chemotherapy tolerability in current study cohorts [28e41]. How-
ever, given the well-established safety proﬁle [13,31,35] and
improved patient outcomes observed [28e41] including n-3 PUFA
supplements as standard of care in speciﬁc patients is proposed. For
example, although clear mechanisms of action have not yet beenestablished, clinical trials collectively suggest improved outcomes
with n-3 PUFA supplementation in lung cancer patients undergoing
chemotherapy [32,35,36,38,40,41].
Human supplementation with ﬁsh oils have consistently been
shown to be safe and tolerable. When provided concurrently with
chemotherapy drugs, beneﬁts to the patient that enable the patient
to complete the best planned course of treatment are observed
[35]. Given the alarming cost of delivering oncological services to
patients [81e83], any means by which to improve treatment out-
comes would be considered to be of economic importance. The
direct and indirect costs increase when toxicities occur during
treatment for cancer. For example, the total cost of a single
chemotherapy-related toxicity event (i.e. neurotoxicity, thrombo-
cytopenia, or neutropenia) has been reported to be between $4908
and $11,830 (USD) [84].
6.2. Examples of potential healthcare cost savings with ﬁsh oil
supplementation
A 2008 study revealed that the most cost effective means of
increasing EPA and DHA intakewas in the form of encapsulated ﬁsh
oil [80]. They determined that encapsulated ﬁsh oil containing EPA
(~0.6 g) and DHA (~0.4 g) has an average cost of $0.41 (USD) per
gram [80], which is consistent with current market costs.
We performed a phase II clinical trial investigating n-3 PUFA
supplementation in patients undergoing ﬁrst line chemotherapy
for treatment of non-small cell lung cancer [35]. Patients were
treated at the Cross Cancer Institute (Edmonton, Canada), where
ﬁrst line treatment for stage IIIB and IV non-small cell lung cancer is
carboplatinum/vinorelbine chemotherapy, given over 4 cycles
(12e16 weeks). Therefore, the estimated cost of n-3 PUFA supple-
mentation (>2 g of EPA per day) over the course of chemotherapy
treatment in this studywas between $137.76 and $183.68 (USD) per
patient (i.e. $0.41 per gram of ﬁsh oil  4 g of ﬁsh oil per day to
achieve >2 g of EPA  12 and 16 weeks). We observed that 39% of
patients receiving standard of care experienced chemotherapy-
related toxicities, while only 20% of patients taking n-3 PUFA sup-
plementation experienced toxicities [35]. Taking into consideration
the cost of n-3 PUFA supplementation, the incidence of
chemotherapy-related toxicities, and the cost of a single
chemotherapy-related toxicity, the following formula was used to
determine the potential chemotherapy-related toxicity cost savings
of n-3 PUFA supplementation:
[(cost of a single chemotherapy-related toxicity  proportion of
patients receiving standard of care that experienced toxicity)] e
[(cost of a single chemotherapy-related toxicity þ cost of n-3 PUFA
supplementation over the course of chemotherapy
treatment)  proportion of patients receiving n-3 PUFA supple-
mentation that experienced toxicity].
From our example, it is estimated that $904.97 to $2210.96
(USD) of direct and indirect costs can be saved from a single
toxicity-related event per patient undergoing chemotherapy for
advanced non-small cell lung cancer. When considering that at our
single cancer center, approximately 200 patients per year receive
this drug combination for a lung cancer diagnosis, this would
amount to a cost savings of over $300,000 (USD) in one year for this
single tumor treatment combination alone.
As another example, Bougnoux et al. [31] conducted a phase II
clinical trial investigating DHA supplementation in patients with
advanced breast cancer undergoing anthracycline-based chemo-
therapy. Patients consumed capsules containing a total of 1.8 g of
DHA per day for approximately 23 weeks, costing a total of $330.05
(USD) per patient (i.e. $0.41 per gram of ﬁsh oil  5 g of ﬁsh oil per
day to achieve 1.8 g of DHA  23 weeks). Those patients with high
DHA incorporation experienced signiﬁcantly less chemotherapy-
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which has been shown to cost $7550 (USD)/per patient episode for
this speciﬁc toxicity [84]. Supplementationwith DHA could provide
an average cost savings of approximately $3846.38 (USD) per pa-
tient in chemotherapy-related thrombocytopenia toxicities alone
occurring in breast cancer patients. Patients with high DHA incor-
poration in this study also experienced signiﬁcantly less
chemotherapy-related anemia, and therefore the cost savings for
this patient population may be even greater.
Not included in this cost estimate is the potential additional cost
savings associated with improved nutritional status that is
observed in cancer patients supplementing with n-3 PUFA under-
going chemotherapy [29,30,32,34,36e40]. Additional health care
costs are associated with patients who experience declines in
nutritional status as this can result in unplanned hospital admis-
sions as well as longer hospital stays [85].
7. Conclusion
Although its safety proﬁle has been well-established, clinical
trials have yet to deﬁne reasons why n-3 PUFA supplementation
improves chemotherapy tolerability. Several barriers have led to
difﬁculty deﬁning these mechanisms, including small study sizes,
variations in supplement dosage and methodology, and differences
in primary outcome measures. Based on the limited evidence
available from human studies, mechanisms of action may include
modulation of membrane-associated functions, reduction of
gastrointestinal side effects of chemotherapy and maintenance of
skeletal muscle mass. However, there is currently insufﬁcient evi-
dence to conﬁrm these mechanisms. Side effects related to
chemotherapy lead to increased unplanned hospital admissions
and thus increased costs to the healthcare system. Therefore,
implementing an intervention shown to improve chemotherapy
tolerability and patient outcomes could mitigate some of these
costs. Combined with the well-validated safety proﬁle and prom-
ising results of several recent clinical trials, we believe that this
warrants increased use of n-3 PUFA supplements as adjuvants to
chemotherapy due to their positive effects on chemotherapy
tolerability and improved patient outcomes.
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